Lv3
220 积分 2025-03-03 加入
Drug-eluting beads TACE is safe and non-inferior to conventional TACE in HCC patients with TIPS
13小时前
待确认
Identifying optimal candidates for post-TIPS patients with HCC undergoing TACE: a multicenter observational study
13小时前
待确认
Surgical Site Infections, Risk Factors, and Outcomes After Liver Transplant
2天前
已完结
Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study
1个月前
已完结
Anthropometric indicators of adiposity and risk of primary liver cancer: A systematic review and dose–response meta-analysis
1个月前
已完结
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study
2个月前
已完结
Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial
5个月前
已完结
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study
9个月前
已完结
Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH)
9个月前
已完结
皖公网安备34019202002308
